The company’s strategy to strengthen its position and establish strong relationships with five reference customers in the USA has now resulted in one of the country’s leading health institutes ordering an upgrade from their Attana Cell™ 200 to Attana Cell™ 250. The order will impact Q1 results and Q2 cashflow.
The purpose of the upgrade is to streamline ongoing research projects. The primary goal for the customer is to enhance palliative care for cancer patients by donating T-cells from healthy individuals to the patients. The Company’s technology is utilized to study interactions between human and animal T-cells with cancer cells and cancer tissue, expediting the transition from animal experiments to clinical trials. Ultimately, it can be used for personalized donation, thereby increasing the number of potential donors for a given patient.
I am very satisfied that our US-strategy is yielding results both financially and scientifically. The order is further evidence that our technology generates unique and valuable biological data. We look forward to continuing collaboration with the customer and strengthening our position in US, says Marcus Söderberg, CEO of Attana
